Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.52M
Average 1.55M
ORKA Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Oruka Therapeutics, Inc.NASDAQ: ORKA
Gross Profit · Q3 FY2026 · quarter ended Sep 2026
Gross profit turns negative
Q3 FY2026 gross profit was -$62.14M, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$62.25M.
Context
- Gross profit grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly gross profit holds near -$62.14M or moves back toward the trailing-twelve-month quarterly average of -$15.56M.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (83K) USD
- Year-over-year change
- -207.4%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (83K) | -207.4% |
| FY2024 | 2024-12-31 | (27K) | +75.7% |
| FY2023 | 2023-12-31 | (111K) | +2.6% |
| FY2022 | 2022-12-31 | (114K) | -25.3% |
| FY2021 | 2021-12-31 | (91K) | — |
Gross Profit vs competitors
How ORKA compares with its peers on the latest reported figures
- ORKA's LTM Sep 2026 gross profit of -$62.25M is the lowest of the 10 companies compared; the peer median is $1.83M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $270.54M | +582.2% | — | 116.4% | |
| LTM Jun 2026 | $45.46M | -54.8% | — | 43.3% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $6.53M | -66.1% | — | 88.2% |
| LTM Mar 2026 | $6.39M | +74.8% | -31.4% | 76.3% | |
| LTM Jun 2026 | $1.83M | -62.3% | -31.8% | 96.0% | |
| FY2025 | $546K | +274.4% | — | 40.4% | |
| FY2025 | $64K | -99.8% | — | 100.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$16K | -220.0% | — | — |
| LTM Mar 2026 | -$2.34M | -7090.5% | — | — | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | -$62.25M | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ORKA) | $1.83M | -62.3% | -31.6% | 88.2% | |
Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 91K | 114K | 111K | 27K | 83K |
| Gross Profit | (91K) | (114K) | (111K) | (27K) | (83K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.83M | 4.46M | 1.01M | 75.06M | 100.64M |
| Selling, General & Admin | 5.41M | 5.26M | 6.17M | 13.04M | 21.33M |
| Operating Expenses | 19.24M | 9.73M | 7.19M | 88.1M | 121.97M |
| Depreciation & Amortization | 91K | 114K | 111K | 27K | 83K |
| EBITDA | (19.23M) | (9.81M) | (5.23M) | (82.23M) | (105.35M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.34M) | (9.84M) | (7.3M) | (88.12M) | (122.05M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 675K | 1.96M | 5.86M | 16.63M |
| Interest Expense | 0 | 0 | 0 | 1.47M | 0 |
| Other Income / Expenses | 13K | (85K) | 1.96M | 4.4M | 16.62M |
| Income Before Tax | (19.32M) | (9.93M) | (5.34M) | (83.72M) | (105.43M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.32M) | (9.93M) | (5.34M) | (83.72M) | (105.43M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (16.68) | (8.27) | (4.44) | (4.99) | (2.31) |
| EPS (Diluted) | (16.68) | (8.27) | (4.44) | (4.99) | (2.31) |
| Weighted Avg Shares | 13.9M | 14.41M | 14.42M | 16.79M | 45.61M |
| Weighted Avg Shares (Diluted) | 13.9M | 14.41M | 14.42M | 16.79M | 45.61M |
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$95.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.